James Hattersley

SVP, Corporate Business Development, Mission Pharmacal Company

James E. Hattersley currently serves as SVP, Corporate Development at Mission Pharmacal Company.  Primary focus is growth strategy in key therapeutic categories including dermatology, urology, and women's health with additional selective focus in ophthalmology.

Before Mission Pharmacal, James served as SVP of Business Development at Iota Biosciences (bioelectronic medicine) and Santen (ophthalmology), both preceded by his tenure as SVP Business Development at Adherium - a global digital health adherence outcomes organization directly responsible for establishing Adherium North America.  Prior to Adherium, Mr. Hattersley held the position of Vice President of Business Development at Nektar Therapeutics accountable for business development, corporate strategic alliances, alliance management, and commercial partnerships for late stage clinical assets in oncology, ophthalmology, and pain management.  Before Nektar, James served for several years as Vice President of Business Development at Sun Pharmaceutical Industries directly responsible for acquisitions and strategic partnerships in North America, and out-licensing of oncology, ophthalmology, CNS, and respiratory opportunities in Japan territory.

Mr. Hattersley has over 25 years of successful leadership experience in life sciences, with a proven track record of identifying and executing deals of significant value.  During the course of his career James has successfully completed numerous revenue-generating transactions involving SMid and Large biotech/pharma organizations.  Mr. Hattersley earned graduate and undergraduate academic degrees in biochemistry and neurobiology, respectively, from the University of California.  In addition, James successfully completed post-graduate financial analytics program at University of Chicago GSB.


MeEt Us

View our upcoming events

View All Events